Market research
DXCM DexCom Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 34B
- P/E ratio
- 36.42
- Analyst target
- 94.12
- Dividend yield
- Not available
- Beta
- 1.41
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US2521311074
- Market cap
- 34B
- P/E ratio
- 36.42
- Analyst target
- 94.12
- Dividend yield
- Not available
- Beta
- 1.41
About
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DXCM discussion.
5 years, 4 months ago
DexCom, Inc is currently in a long term uptrend where the price is trading 19.7% above its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 18.6.
DexCom, Inc's total revenue rose by 22.9% to $569M since the same quarter in the previous year.
Its net income has increased by 283.2% to $355M since the same quarter in the previous year.
Finally, its free cash flow grew by 12.2% to $112M since the same quarter in the previous year.
Based on the above factors, DexCom, Inc gets an overall score of 5/5.